Short answer
What is a DSIP research peptide? DSIP (delta sleep-inducing peptide) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated from brain and studied in sleep and neuroendocrine research for its reported influence on slow-wave (delta) sleep. It is sold as a lyophilized research powder and is not for human use.
DSIP: chemical identity and structure
DSIP (delta sleep-inducing peptide) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, a molecular weight of approximately 849 Da, and CAS number 69431-45-4. It is a linear peptide with no cysteine residues and no disulfide bridge, which distinguishes it structurally from cyclic neuropeptides such as oxytocin [1]. Its sequence is not closely related to any other known peptide family, which has made its biology difficult to place within established peptide systems [4]. In contrast to neurohypophysial nonapeptides such as oxytocin, DSIP is neither C-terminally amidated nor cyclized, and its synthesis is comparatively straightforward, which makes purity and exact sequence the main quality considerations for research material.
Discovery and research history
DSIP was isolated in 1977 by the Basel group of Schoenenberger and Monnier from the cerebral venous blood of rabbits subjected to electrical stimulation of the intralaminar thalamus, a manipulation that induces slow-wave (delta) sleep [2]. The isolation followed earlier work establishing that delta sleep could be transferred humorally via cerebrospinal dialysate from sleeping donor rabbits. In the 1977 characterization, intraventricular infusion of the synthetic nonapeptide enhanced delta and spindle EEG activity in rabbits, and structure-activity experiments showed that only the full sequence, and not metabolic fragments or sequence variants, produced this effect [2]. Species differences were apparent even in the early work: in rabbits, rats, mice, and humans the reported effects centered on delta (slow-wave) sleep, whereas in cats effects on REM sleep predominated [1][2].
A follow-up study in the same year demonstrated that the synthetic peptide crosses the blood-brain barrier, since systemic (intravenous) administration of 30 nmol/kg DSIP significantly increased cortical delta activity in freely moving rabbits [3].
DSIP in sleep research
The peptide's name reflects its reported origin as a sleep factor, and the early literature describes effects on slow-wave (delta) sleep. The 1984 review by Graf and Kastin surveys this body of work, describing reported effects on delta sleep in rabbits, rats, mice, and humans, while noting that in cats effects on REM sleep predominated [1]. The review also describes a U-shaped relationship between the amount administered and the response, meaning effects did not scale monotonically with the quantity given [1].
It is important for researchers to know that the sleep literature on DSIP is not uniform. Later analysis by Kovalzon and Strekalova characterized DSIP as a still unresolved riddle, noting that the link between DSIP and sleep remains poorly documented because the DSIP gene, protein, and receptor have never been identified [4]. This framing is widely cited and is the appropriate context for interpreting the older sleep studies [4]. Reports in human subjects were based on small samples and did not consistently reproduce the effects seen in animal models, and the link between DSIP and sleep remains poorly documented [1][4].
DSIP-like immunoreactivity and the search for endogenous material
A notable feature of the DSIP literature is that DSIP-like immunoreactivity has been detected widely, not only in brain but in peripheral organs and plasma across several mammalian species [1]. The Graf and Kastin review already documented the presence of DSIP-like material in these compartments using radioimmunoassay and immunohistochemistry [1]. Because no precursor gene has been confirmed, biosynthetic studies suggest endogenous DSIP-like immunoreactivity may correspond to larger, glycosylated precursor material rather than the free nonapeptide [4]. This has led to the hypothesis that DSIP-like peptides, structurally related but not identical to DSIP, may be the actual endogenous effectors, and that the free nonapeptide studied in the laboratory may be one member of a larger family [4].
Broader neuroendocrine and physiological research
Beyond sleep, the peptide has been studied for a range of physiological effects. The Graf and Kastin review summarizes reported influences on electrophysiological activity, brain neurotransmitter levels, circadian and locomotor patterns, hormonal systems, psychological performance, and interactions with neuropharmacological agents [1]. Because the review was published in 1984, it consolidates the first decade of research and remains the standard starting point for researchers entering the field [1].
The breadth of these reported effects, combined with the absence of an identified receptor or precursor gene, is precisely why DSIP remains a subject of active interest in neuropeptide research: it is an orphan molecule with a large but heterogeneous literature [4]. Reported effects in the broader physiological sphere include influences on psychological performance and interactions with neuropharmacological agents, in addition to the hormonal and circadian measures covered in the review [1].
Neuroendocrine and stress-related research on DSIP
Beyond sleep, DSIP has been studied for its reported effects on hormonal systems and on the neuroendocrine axis. The 1984 review already placed DSIP in this broad physiological context, and subsequent research explored these themes further, particularly the relationship between DSIP and stress-related processes and its reported interactions with neuropharmacological agents [1][4]. Because these studies span sleep, stress, and neuroendocrine research, DSIP has historically been positioned as a neuromodulator rather than a classic hormone or neurotransmitter. The Kovalzon and Strekalova analysis emphasizes that the absence of a confirmed receptor and precursor has kept this positioning provisional [4].
Open questions in DSIP research
Three central unknowns define the current DSIP research landscape:
For researchers, these open questions mean DSIP is best understood as a research peptide whose name reflects its history rather than a settled mechanism, and whose study requires careful attention to the primary literature.
Experimental considerations in DSIP research
Researchers working with DSIP should account for several features of the literature when designing experiments:
DSIP compared with related research peptides
DSIP is one of several neuropeptides studied in sleep and neuroendocrine research:
DSIP is often grouped with other neuropeptides and short regulatory peptides, and the neuropeptide research category provides a starting point for comparing related compounds. The lyophilized research-grade DSIP is available on the DSIP product page.
For an overview of the neuropeptide category, see neuropeptide research and what are peptides.
How to evaluate research-grade DSIP
DSIP is a linear nonapeptide that is straightforward to synthesize, so purity is the main quality consideration:
Because DSIP is a simple linear peptide with no post-translational modifications, sequence verification by mass spectrometry is the decisive quality control step. Suppliers should provide the measured mass alongside the HPLC trace, and the certificate of analysis should be specific to the batch received. Lyophilized material is preferred for stability during shipping, and reconstituted solutions should be prepared fresh and used within the time frame specified by the protocol.
For interpreting purity data, see peptide COA guide and HPLC vs mass spectrometry peptide purity.
Storage and handling
Lyophilized DSIP is stable under standard peptide storage conditions:
For a detailed protocol, see peptide reconstitution and laboratory handling and how to store peptides.
Summary
DSIP is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) isolated from rabbit brain and studied for its reported influence on slow-wave (delta) sleep and a range of neuroendocrine and physiological parameters. Its research history spans the 1977 isolation, the 1984 Graf and Kastin review, and modern analyses describing it as a still-unresolved molecule with no identified receptor or precursor. Laboratory-grade DSIP should be verified for HPLC purity, mass-spectrometry identity, exact sequence, and batch-specific COA.
FAQ
What is DSIP?
DSIP (delta sleep-inducing peptide) is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (~849 Da, CAS 69431-45-4), isolated from brain and studied in sleep research.
How was DSIP discovered?
DSIP was isolated in 1977 from the cerebral venous blood of rabbits undergoing slow-wave-sleep-inducing thalamic stimulation, and was shown to enhance delta EEG activity upon intraventricular infusion.
What is DSIP studied for in research?
DSIP is studied in sleep research for its reported effects on slow-wave (delta) sleep, and in neuropeptide research for its reported neuroendocrine and physiological effects, including influences on hormonal systems.
What purity should research-grade DSIP have?
Look for at least 98% purity by HPLC, mass-spectrometry identity confirmation, exact sequence verification, and a batch-specific COA.